GHRS News

16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity (DOCS), which soared 104% in its debut. The week’s IPOs were joined by four SPACs, as well as one postponement, Chinese social networking platform Soulgate (SSR). Doximity (DOCS) priced above the range to raise...read more

GH Research, a Phase 2 biotech developing DMT-based therapies for depression, raised $160 million by offering 10 million shares at $16, the high end of the range of $14 to $16. The company offered 1.7 million more shares than anticipated. The company is developing its proprietary 5-MeO-DMT compound in a Phase 2 trial in the Netherlands for patients with Treatment-Resistant...read more

GH Research, a Phase 2 biotech developing DMT-based therapies for depression, announced terms for its IPO on Monday. The Dublin, Ireland-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, GH Research would command a fully diluted market value of $733 million. The company is developing its...read more

Just one IPO entered public markets after the holiday weekend, but the pipeline remained active, with 14 IPOs and 10 SPACs submitting initial filings. Cross-border payment processor dLocal (DLO) priced well above the range to raise $618 million at a $6.2 billion market cap. The Uruguay-based company provides a safe and simple platform for global...read more